Featured
Last news
Surgical Information Systems (SIS) Earns Eleventh Consecutive #1 Client Rating in Ambulatory Surgical Center IT User Satisfaction, Black Book 2026 Survey
TAMPA, FLORIDA / ACCESS Newswire / January 20, 2026 / Black Book Research today announced that Surgical Information Systems (SIS) has again been rated #1 overall in Ambulatory Surgical Center (ASC) health IT user satisfaction-marking its eleventh consecutive year as the top-rated vendor in this category, based on validated end-user survey feedback.
Vanderbilt Report: VisionWave Holdings Addresses Critical Defense Speed Gap as AI Military Market Accelerates to $35.78 Billion by 2034
Decision Speed Emerges as Defining Advantage in Modern Defense Architecture
Saint Therese of Oxbow Lake Earns 2025 Zellner Group Client of the Year Award
Brooklyn Park, MN senior care community recognized for exceptional partnership, leadership, and commitment to resident-centered care
BNP Media Strengthens Mechanical Systems Industry Portfolio Through Leadership Alignment
Expanded group publisher role reflects how HVAC, plumbing, and mechanical systems professionals operate today.
Black Book Research Releases "New Zealand Acute Care EMR & Digital Health 2026" Companion Report
New analysis details the national platforms, standards, and vendor landscape shaping EMR consolidation, interoperability, medicines safety, and cyber resilience across Aotearoa New Zealand
Pivotree Partners with OroCommerce to Deliver Unmatched B2B eCommerce Powered by Mastered Data
TORONTO, ONTARIO / ACCESS Newswire / January 20, 2026 / Pivotree, a leader in frictionless commerce, today announced an official partnership with OroCommerce, the industry's most powerful B2B-native digital commerce platform. This partnership creates the most complete B2B implementation and integration offering on the market, uniquely combining a best-in-class platform with expert-led product information management (PIM/MDM) and data enrichment services. The partnership comes as B2B organizations increasingly modernize commerce platforms while addressing the data foundations required to support automation, AI-driven workflows, and scalable digital growth.
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu RxConnect® pharmacies to support patient access
Dolphin Subsidiary 42West Brings Exciting and Diverse Projects to the 2026 Sundance Film Festival
LOS ANGELES, CALIFORNIA / ACCESS Newswire / January 20, 2026 / The entertainment PR and marketing powerhouse 42West, a subsidiary of Dolphin (NASDAQ:DLPN), will showcase a number of impressive clients with film and television projects premiering at the 2026 Sundance Film Festival, running in Park City from January 22 to February 1.
New to The Street(TM) Delivers Record-Breaking January 2026 With 22 Companies Signing and Renewing Series, Television and Outdoor Billboard Programs
NEW YORK CITY, NEW YORK / ACCESS Newswire / January 20, 2026 / New to The Street, the long-running, multi-platform business and financial media brand, today announced a record-breaking January 2026, with 22 companies signing new agreements and/or renewing for ongoing series participation, standalone television broadcasts, and/or iconic outdoor billboard programs during the month.
Specificity Achieves Positive Cash Flow and Unveils Strategic Growth Initiatives for 2026
SARASOTA, FLORIDA / ACCESS Newswire / January 20, 2026 / Specificity (OTCID:SPTY), a leading hybrid AdTech company specializing in bot-free, intent-based digital marketing solutions, today announced a series of milestones that underscore its robust financial health and positioning for accelerated growth in the coming year. These developments highlight the company's commitment to delivering superior value to clients and shareholders alike, amid a rapidly evolving digital advertising landscape plagued by fraud and inefficiency.
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acneDermata expects to launch a new once-weekly, over-the-counter (OTC) acne treatment system, incorporating its Spongilla technology, in the middle of 2026, first in the U.S.Over 3.3 million people are diagnosed with acne in Australia
FendX Technologies Presenting at the 3rd Annual DealFlow Discovery Conference
ATLANTIC CITY, NJ AND VANCOUVER, BC / ACCESS Newswire / January 20, 2026 / FendX Technologies Inc.(CSE:FNDX)(OTCQB:FDXTF)(FSE:E8D) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, announces that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference
SHELTON, CT / ACCESS Newswire / January 20, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will participate in the DealFlow Discovery Conference, taking place January 28th and 29th, 2026.
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disordersAlprazolam, sold under the brand name Xanax® among others, was the 37th most commonly prescribed medication in the United States, with more than 15.8 million combined branded and generic prescriptions in 2023Phase 1 clinical trial planned for mid-2026
The Fresh Factory Announces Closing of US$3 Million Non-Brokered Private Placement and Increase Funds Under Existing Credit Facility
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Kronos Advanced Technologies, Inc. (OTC: KNOS) Reports Fiscal 2025 Revenue of Controlled Subsidiary Zyppah, Inc
LOS ANGELES, CA / ACCESS Newswire / January 20, 2026 / Kronos Advanced Technologies, Inc. ("Kronos" or the "Company") (OTC PINK:KNOS), a leader in innovative health and wellness technologies, today reported that its controlled subsidiary, Zyppah, Inc.
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510; [95% CI, 0.294-0.887]) compared to KEYTRUDA aloneThe Companies plan to present further data from follow up analyses of the study's primary and secondary endpoints at a future medical conferenceEight Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma
Allies tepid on Trump 'Board of Peace' with $1bn permanent member fee
Key allies reacted coolly Monday to US President Donald Trump's invite to pay $1 billion for a permanent spot on his "Board of Peace" for resolving international conflicts, with analysts likening it to a pay-to-play version of the UN Security Council.
Ninth policeman dies in Guatemala gang riots, attacks
Authorities in Guatemala said Monday a ninth police officer died of his injuries following an outbreak of gang violence, over which the government declared a state of emergency.
Spain seeks answers as high-speed train crash toll rises to 40
The death toll from a high-speed train collision in southern Spain rose to 40 on Monday as the government vowed a full investigation into its causes.
Allies tepid on Trump 'peace board' with $1bln permanent member fee
Key allies reacted coolly Monday to US President Donald Trump's invite to pay $1.0 billion for a permanent spot on his "Board of Peace" for resolving international conflicts, with analysts likening it to a pay-to-play version of the UN Security Council.
Ex-OPEC president in UK court ahead of corruption trial
Former OPEC president Diezani Alison-Madueke appeared in a London court on Monday, ahead of her full trial on bribery charges relating to her time as Nigeria's oil minister.
Prince Harry, Elton John 'violated' by UK media's alleged intrusion
Alleged unlawful information gathering by two UK newspapers made Prince Harry "paranoid beyond belief" and left Elton John feeling "violated", the pair have testified as a joint lawsuit opened Monday in the High Court.
New charges against son of Norway princess
The son of Norway's crown princess, who goes on trial in February accused of raping four women, has been charged with new crimes including a "serious narcotics offence", the prosecutor said on Monday.
Trump to charge $1bn for permanent 'peace board' membership
US President Donald Trump's government has asked countries to pay $1.0 billion for a permanent spot on his "Board of Peace" aimed at resolving conflicts, according to its charter, seen Monday by AFP.
Over 400 Indonesians 'released' by Cambodian scam networks: ambassador
More than 400 Indonesians were freed by cyberscam networks in Cambodia this month, Jakarta said on Monday, after Phnom Penh announced a fresh crackdown following the arrest of an alleged boss of the illicit industry.
High-speed train collision in Spain kills 39, injures dozens
A high-speed train derailed and was hit by another in southern Spain killing 39 people and injuring more than 120, authorities said Monday, saying the country's worst train in over a decade was "extremely strange".
Trustpoint Xposure Documents How a Law Firm Became the Default Choice Before the First Call
How AI Driven Discovery and Authority Recognition Reshaped Client Selection in Legal Services
Desert Oasis Healthcare Supports Release of 7th Coachella Valley Community Health Survey, Advancing Data-Driven Community Impact
DOHC continues its longstanding commitment to community health by supporting region's most comprehensive health data resource
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it has completed and received preliminary results from its comparative pharmacokinetics ("PK") large-mass animal study in pigs. The study measured how efficiently cladribine is absorbed into the bloodstream over time and compared BioNxt's proprietary orally dissolving film ("ODF") with the reference tablet formulation, evaluating the Company's swallow-free, sublingual ODF formulation for Multiple Sclerosis (MS).
Genflow Biosciences PLC Announces Directorate Change
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Genflow Biosciences PlcGenflow Appoints a New Chairman to Accelerate Corporate and R&D Expansion
PolyPeptide Successfully Closes Financial Year 2025 With Strong Revenue Growth and Marked Improvement in Profitability
BAAR, CH / ACCESS Newswire / January 19, 2026 / PolyPeptide Group AG (SIX:PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its financial year 2025.